Specific features of antimicrobial therapy in patients with severe respiratory failure receiving veno-venous extracorporeal membrane oxygenation (ECMO)

M.A. Petrushin, P.I. Melnichenko, P.A. Vlasov, I.S. Nikiforov, E.A. Kudryashova, I.A. Glushchenko
{"title":"Specific features of antimicrobial therapy in patients with severe respiratory failure receiving veno-venous extracorporeal membrane oxygenation (ECMO)","authors":"M.A. Petrushin, P.I. Melnichenko, P.A. Vlasov, I.S. Nikiforov, E.A. Kudryashova, I.A. Glushchenko","doi":"10.36488/cmac.2023.2.171-177","DOIUrl":null,"url":null,"abstract":"In modern medicine, the extracorporeal membrane oxygenation (ECMO) is becoming increasingly common in the treatment of severe respiratory failure. The development of infectious complications in patients receiving ECMO often leads to an increase in the duration of the procedure and significantly increases the risk of death. Dosing of antimicrobials during ECMO remains uncertain and requires further research. Diagnosis of infectious complications during ECMO is a difficult and requires the development of diagnostic protocols and the use of routine microbiological studies. The use of antimicrobials during ECMO could be complicated due to decrease in effective plasma concentration. The adsorption of antibacterial drugs in the ECMO circuit and oxygenator, the use of infusion therapy, the development of hypoalbuminemia, as well as the high incidence of acute renal and hepatic dysfunction in critically ill patients lead to an inevitable change in the volume of distribution and clearance of antibacterial drugs. These conditions require an individual approach to the choice of antimicrobials and optimization of dosing regimens in critically ill patients receiving ECMO.","PeriodicalId":53392,"journal":{"name":"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36488/cmac.2023.2.171-177","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In modern medicine, the extracorporeal membrane oxygenation (ECMO) is becoming increasingly common in the treatment of severe respiratory failure. The development of infectious complications in patients receiving ECMO often leads to an increase in the duration of the procedure and significantly increases the risk of death. Dosing of antimicrobials during ECMO remains uncertain and requires further research. Diagnosis of infectious complications during ECMO is a difficult and requires the development of diagnostic protocols and the use of routine microbiological studies. The use of antimicrobials during ECMO could be complicated due to decrease in effective plasma concentration. The adsorption of antibacterial drugs in the ECMO circuit and oxygenator, the use of infusion therapy, the development of hypoalbuminemia, as well as the high incidence of acute renal and hepatic dysfunction in critically ill patients lead to an inevitable change in the volume of distribution and clearance of antibacterial drugs. These conditions require an individual approach to the choice of antimicrobials and optimization of dosing regimens in critically ill patients receiving ECMO.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重症呼吸衰竭患者接受静脉-静脉体外膜氧合(ECMO)抗菌治疗的特异性分析
在现代医学中,体外膜氧合(ECMO)在严重呼吸衰竭的治疗中越来越普遍。在接受ECMO的患者中,感染性并发症的发生通常会导致手术时间的延长,并显著增加死亡风险。ECMO期间抗菌剂的剂量仍不确定,需要进一步研究。ECMO期间感染性并发症的诊断是一个困难的,需要制定诊断方案和使用常规微生物学研究。由于有效血浆浓度降低,ECMO期间抗菌素的使用可能会变得复杂。抗菌药物在ECMO回路和氧合器中的吸附,输液治疗的使用,低白蛋白血症的发展,以及危重患者急性肾功能和肝功能障碍的高发,导致抗菌药物的分布量和清除率发生不可避免的变化。这些情况需要在接受体外膜肺治疗的危重患者中选择单独的抗菌剂和优化给药方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
Current approaches and prospects for the development of laboratory diagnosis of measles The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam Prospects for the use of statins in antiviral therapy AMRexpert – online platform for interpretation, verification and validation of antimicrobial susceptibility testing Anti-staphylococcal activity and cytocompatibility of lysostaphin
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1